Cargando…
Adiponectin to leptin ratio reflects inflammatory burden and survival in COVID-19
AIM: Obesity is a risk factor for COVID-19, but the underlying mechanisms are unclear. We investigated the role of adiponectin (an anti-inflammatory adipokine), leptin (a pro-inflammatory adipokine) and their ratio (Adpn/Lep) in this context. DESIGN: Single-centre, prospective observational study. M...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Masson SAS.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8320244/ https://www.ncbi.nlm.nih.gov/pubmed/34333093 http://dx.doi.org/10.1016/j.diabet.2021.101268 |
_version_ | 1783730612075495424 |
---|---|
author | Di Filippo, Luigi De Lorenzo, Rebecca Sciorati, Clara Capobianco, Annalisa Lorè, Nicola I. Giustina, Andrea Manfredi, Angelo A. Rovere-Querini, Patrizia Conte, Caterina |
author_facet | Di Filippo, Luigi De Lorenzo, Rebecca Sciorati, Clara Capobianco, Annalisa Lorè, Nicola I. Giustina, Andrea Manfredi, Angelo A. Rovere-Querini, Patrizia Conte, Caterina |
author_sort | Di Filippo, Luigi |
collection | PubMed |
description | AIM: Obesity is a risk factor for COVID-19, but the underlying mechanisms are unclear. We investigated the role of adiponectin (an anti-inflammatory adipokine), leptin (a pro-inflammatory adipokine) and their ratio (Adpn/Lep) in this context. DESIGN: Single-centre, prospective observational study. Methods. Adiponectin and leptin were measured in 60 COVID-19 patients with mild (not hospitalised, n=11), moderate (hospitalised but not requiring intensive care, n=25) and severe (admission to the intensive care unit [ICU] or death, n=24) disease. RESULTS: Adiponectin and leptin levels were similar across severity groups, but patients with moderate severity had the highest Adpn/Lep ratio (1.2 [0.5; 2.0], 5.0 [1.6; 11.2], 2.1 [1.0; 3.6] in mild, moderate and severe disease; P = 0.019). Adpn/Lep, but not adiponectin or leptin alone, correlated with systemic inflammation (C reactive protein, CRP: Spearman's rho 0.293, P = 0.023). When dividing patients into Adpn/Lep tertiles, adiponectin was highest, whereas leptin was lowest in the third (highest) tertile. Patients in the highest Adpn/Lep tertile had numerically lower rates of obesity, diabetes and hypertension, and lower rates of death or admission to ICU versus other tertiles. At linear regression in the whole cohort, CRP significantly predicted Adpn/Lep (β 0.291, P = 0.022), while female gender (β -0.289, P = 0.016), diabetes (β -0.257, P = 0.028), and hypertension (β -239, P = 0.043) were negative predictors. CONCLUSIONS: We speculate that the rise in Adpn/Lep, due to increased adiponectin and reduced leptin, is a compensatory response to systemic inflammation. In patients with worse cardiometabolic health (e.g. diabetes, hypertension) this mechanism might be blunted, possibly contributing to higher mortality. |
format | Online Article Text |
id | pubmed-8320244 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier Masson SAS. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83202442021-07-29 Adiponectin to leptin ratio reflects inflammatory burden and survival in COVID-19 Di Filippo, Luigi De Lorenzo, Rebecca Sciorati, Clara Capobianco, Annalisa Lorè, Nicola I. Giustina, Andrea Manfredi, Angelo A. Rovere-Querini, Patrizia Conte, Caterina Diabetes Metab Short Report AIM: Obesity is a risk factor for COVID-19, but the underlying mechanisms are unclear. We investigated the role of adiponectin (an anti-inflammatory adipokine), leptin (a pro-inflammatory adipokine) and their ratio (Adpn/Lep) in this context. DESIGN: Single-centre, prospective observational study. Methods. Adiponectin and leptin were measured in 60 COVID-19 patients with mild (not hospitalised, n=11), moderate (hospitalised but not requiring intensive care, n=25) and severe (admission to the intensive care unit [ICU] or death, n=24) disease. RESULTS: Adiponectin and leptin levels were similar across severity groups, but patients with moderate severity had the highest Adpn/Lep ratio (1.2 [0.5; 2.0], 5.0 [1.6; 11.2], 2.1 [1.0; 3.6] in mild, moderate and severe disease; P = 0.019). Adpn/Lep, but not adiponectin or leptin alone, correlated with systemic inflammation (C reactive protein, CRP: Spearman's rho 0.293, P = 0.023). When dividing patients into Adpn/Lep tertiles, adiponectin was highest, whereas leptin was lowest in the third (highest) tertile. Patients in the highest Adpn/Lep tertile had numerically lower rates of obesity, diabetes and hypertension, and lower rates of death or admission to ICU versus other tertiles. At linear regression in the whole cohort, CRP significantly predicted Adpn/Lep (β 0.291, P = 0.022), while female gender (β -0.289, P = 0.016), diabetes (β -0.257, P = 0.028), and hypertension (β -239, P = 0.043) were negative predictors. CONCLUSIONS: We speculate that the rise in Adpn/Lep, due to increased adiponectin and reduced leptin, is a compensatory response to systemic inflammation. In patients with worse cardiometabolic health (e.g. diabetes, hypertension) this mechanism might be blunted, possibly contributing to higher mortality. Elsevier Masson SAS. 2021-11 2021-07-29 /pmc/articles/PMC8320244/ /pubmed/34333093 http://dx.doi.org/10.1016/j.diabet.2021.101268 Text en © 2021 Elsevier Masson SAS. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Short Report Di Filippo, Luigi De Lorenzo, Rebecca Sciorati, Clara Capobianco, Annalisa Lorè, Nicola I. Giustina, Andrea Manfredi, Angelo A. Rovere-Querini, Patrizia Conte, Caterina Adiponectin to leptin ratio reflects inflammatory burden and survival in COVID-19 |
title | Adiponectin to leptin ratio reflects inflammatory burden and survival in COVID-19 |
title_full | Adiponectin to leptin ratio reflects inflammatory burden and survival in COVID-19 |
title_fullStr | Adiponectin to leptin ratio reflects inflammatory burden and survival in COVID-19 |
title_full_unstemmed | Adiponectin to leptin ratio reflects inflammatory burden and survival in COVID-19 |
title_short | Adiponectin to leptin ratio reflects inflammatory burden and survival in COVID-19 |
title_sort | adiponectin to leptin ratio reflects inflammatory burden and survival in covid-19 |
topic | Short Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8320244/ https://www.ncbi.nlm.nih.gov/pubmed/34333093 http://dx.doi.org/10.1016/j.diabet.2021.101268 |
work_keys_str_mv | AT difilippoluigi adiponectintoleptinratioreflectsinflammatoryburdenandsurvivalincovid19 AT delorenzorebecca adiponectintoleptinratioreflectsinflammatoryburdenandsurvivalincovid19 AT scioraticlara adiponectintoleptinratioreflectsinflammatoryburdenandsurvivalincovid19 AT capobiancoannalisa adiponectintoleptinratioreflectsinflammatoryburdenandsurvivalincovid19 AT lorenicolai adiponectintoleptinratioreflectsinflammatoryburdenandsurvivalincovid19 AT giustinaandrea adiponectintoleptinratioreflectsinflammatoryburdenandsurvivalincovid19 AT manfrediangeloa adiponectintoleptinratioreflectsinflammatoryburdenandsurvivalincovid19 AT roverequerinipatrizia adiponectintoleptinratioreflectsinflammatoryburdenandsurvivalincovid19 AT contecaterina adiponectintoleptinratioreflectsinflammatoryburdenandsurvivalincovid19 |